Tim Anderson
Stock Analyst at Bank of America Securities
(3.91)
# 1,868
Out of 5,189 analysts
257
Total ratings
62.6%
Success rate
5.9%
Average return
Main Sectors:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Reiterated: Buy | $248 → $289 | $286.20 | +0.98% | 22 | Oct 1, 2026 | |
| AARD Aardvark Therapeutics | Reiterated: Buy | $25 | $0.9226 | +2,609.73% | 7 | Dec 18, 2025 | |
| AMLX Amylyx Pharmaceuticals | Reiterated: Buy | $16 → $15 | $26.02 | -42.35% | 3 | Dec 18, 2025 | |
| MLYS Mineralys Therapeutics | Reiterated: Buy | $43 → $46 | $13.66 | +236.75% | 8 | Dec 18, 2025 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $950 → $1,286 | $1,347.11 | -4.54% | 36 | Dec 1, 2025 | |
| MRK Merck & Co. | Reiterated: Buy | $98 → $105 | $133.72 | n/a | 29 | Nov 17, 2025 | |
| MRNA Moderna | Reiterated: Sell | $24 → $21 | $195.00 | n/a | 10 | Nov 10, 2025 | |
| AMGN Amgen | Reiterated: Sell | $272 | $435.64 | n/a | 15 | Nov 5, 2025 | |
| BIIB Biogen | Reiterated: Hold | $167 | $249.59 | n/a | 12 | Nov 3, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Hold | $50 → $52 | $58.80 | n/a | 18 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $543 → $627 | $920.69 | n/a | 14 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $28 → $30 | $27.40 | n/a | 34 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $140 | $166.43 | n/a | 17 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $198 → $204 | $270.47 | n/a | 15 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 11,500p | 13,412p | n/a | 1 | Feb 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | €102.00 → €105.00 | €84.92 | n/a | 2 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $58.46 | n/a | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | CHF 84.00 → CHF 88.00 | CHF 127.76 | n/a | 2 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $150.47 | n/a | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 410.00 → CHF 430.00 | CHF 396.80 | n/a | 2 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $80 → $92 | $22.66 | n/a | 4 | Nov 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $45 | $46.52 | n/a | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | 105,836p | 1,843p | n/a | 1 | Feb 7, 2018 |
AbbVie
Oct 1, 2026
Reiterated: Buy
Price Target: $248 → $289
Current: $286.20
Upside: +0.98%
Aardvark Therapeutics
Dec 18, 2025
Reiterated: Buy
Price Target: $25
Current: $0.9226
Upside: +2,609.73%
Amylyx Pharmaceuticals
Dec 18, 2025
Reiterated: Buy
Price Target: $16 → $15
Current: $26.02
Upside: -42.35%
Mineralys Therapeutics
Dec 18, 2025
Reiterated: Buy
Price Target: $43 → $46
Current: $13.66
Upside: +236.75%
Eli Lilly and Company
Dec 1, 2025
Reiterated: Buy
Price Target: $950 → $1,286
Current: $1,347.11
Upside: -4.54%
Merck & Co.
Nov 17, 2025
Reiterated: Buy
Price Target: $98 → $105
Current: $133.72
Upside: n/a
Moderna
Nov 10, 2025
Reiterated: Sell
Price Target: $24 → $21
Current: $195.00
Upside: n/a
Amgen
Nov 5, 2025
Reiterated: Sell
Price Target: $272
Current: $435.64
Upside: n/a
Biogen
Nov 3, 2025
Reiterated: Hold
Price Target: $167
Current: $249.59
Upside: n/a
Bristol-Myers Squibb Company
Nov 3, 2025
Reiterated: Hold
Price Target: $50 → $52
Current: $58.80
Upside: n/a
Oct 29, 2025
Reiterated: Sell
Price Target: $543 → $627
Current: $920.69
Upside: n/a
Oct 22, 2025
Reiterated: Hold
Price Target: $28 → $30
Current: $27.40
Upside: n/a
Oct 17, 2025
Reiterated: Buy
Price Target: $140
Current: $166.43
Upside: n/a
Oct 15, 2025
Reiterated: Hold
Price Target: $198 → $204
Current: $270.47
Upside: n/a
Feb 19, 2024
Reiterated: Buy
Price Target: 11,500p
Current: 13,412p
Upside: n/a
Jan 3, 2024
Upgraded: Buy
Price Target: €102.00 → €105.00
Current: €84.92
Upside: n/a
Jan 3, 2024
Downgraded: Hold
Price Target: n/a
Current: $58.46
Upside: n/a
May 9, 2022
Downgraded: Hold
Price Target: CHF 84.00 → CHF 88.00
Current: CHF 127.76
Upside: n/a
May 9, 2022
Downgraded: Hold
Price Target: n/a
Current: $150.47
Upside: n/a
Dec 29, 2021
Reiterated: Buy
Price Target: CHF 410.00 → CHF 430.00
Current: CHF 396.80
Upside: n/a
Nov 1, 2021
Reiterated: Buy
Price Target: $80 → $92
Current: $22.66
Upside: n/a
Feb 8, 2018
Reiterated: Hold
Price Target: $45
Current: $46.52
Upside: n/a
Feb 7, 2018
Reiterated: Hold
Price Target: 105,836p
Current: 1,843p
Upside: n/a